SCHEMBL538014

SCHEMBL538014

Fc1nc2ccccc2c(Cl)c1F

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 2/20 0.61
MAOB P27338 1/20 0.61
KDM4E B2RXH2 5/20 0.40
ALDH1A1 P00352 5/20 0.40
TDP1 Q9NUW8 3/20 0.40
GLA P06280 3/20 0.40
HPGD P15428 2/20 0.40
CASP1 P29466 2/20 0.40
CASP7 P55210 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
HSD17B10 Q99714 2/20 0.40
CHRM2 P08172 1/20 0.40
ADRA2A P08913 1/20 0.40
ADORA3 P0DMS8 1/20 0.40
CHRM1 P11229 1/20 0.40
NQO2 P16083 1/20 0.40
DRD1 P21728 1/20 0.40
ACHE P22303 1/20 0.40
SLC6A2 P23975 1/20 0.40
ADRA1A P35348 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19575361 0.83 MAOA (0.61) MAOAMAOBKDM4EALDH1A1TDP1
SCHEMBL15058512 0.80 KDM4E (0.44) MAOAMAOBKDM4EALDH1A1TDP1
SCHEMBL30528247 0.80 KDM4E (0.44) MAOAMAOBKDM4EALDH1A1TDP1
SCHEMBL1758027 0.80 MAOA (0.57) MAOAMAOBKDM4EALDH1A1TDP1
SCHEMBL28360035 0.78 KDM4E (0.43) MAOAMAOBKDM4EALDH1A1TDP1
SCHEMBL455949 0.77 MAOA (1.00) MAOAMAOBKDM4EALDH1A1TDP1
SCHEMBL9258832 0.76 ALDH1A1 (0.55) MAOAMAOBKDM4EALDH1A1GLA
SCHEMBL2171949 0.75 KDM4E (0.40) MAOAMAOBKDM4EALDH1A1TDP1
SCHEMBL538767 0.75 KDM4E (0.40) MAOAMAOBKDM4EALDH1A1TDP1
SCHEMBL13943889 0.75 ALDH1A1 (0.49) MAOAMAOBKDM4EALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8598159-B2 Therapeutic pyrazoloquinoline derivatives DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2013-12-03 US disclosed
EP-2166852-B1 THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES HELICON THERAPEUTICS INC (US) 2012-02-08 EP disclosed
US-20110065693-A1 THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES HELICON THERAPEUTICS, INC. (US) 2011-03-17 US disclosed
US-7872002-B2 Therapeutic pyrazoloquinoline derivatives HELICON THERAPEUTICS, INC. (US) 2011-01-18 US disclosed
EP-2166852-A1 THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES Helicon Therapeutics, Inc. (US) 2010-03-31 EP disclosed
WO-2008154438-A1 THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES HELICON THERAPEUTICS, INC. (US) 2008-12-18 WO disclosed
US-20080306049-A1 THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES HELICON THERAPEUTICS, INC. (US) 2008-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306049-A1 THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES GABRA5, GABRB1, GABRB2 MAOA 484/4885MAOB 350/4885KDM4E 2910/4885
US-20110065693-A1 THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES GABRA5, GABRB1, GABRB2 MAOA 484/4885MAOB 350/4885KDM4E 2910/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.